Early atherosclerosis in a chronic proteasome inhibition model lacks association with vasa vasorum neovascularisation

Standard

Early atherosclerosis in a chronic proteasome inhibition model lacks association with vasa vasorum neovascularisation. / Südfeld, Stefan; Wang, F.; Hermann, J.; Loeffler, D.; Lerman, L.O.; Lerman, A.

in: EUR HEART J, Jahrgang 37 , Nr. (Abstract Supplement), 2016, S. 21.

Publikationen: SCORING: Beitrag in Fachzeitschrift/ZeitungKonferenz-Abstract in FachzeitschriftForschungBegutachtung

Harvard

Südfeld, S, Wang, F, Hermann, J, Loeffler, D, Lerman, LO & Lerman, A 2016, 'Early atherosclerosis in a chronic proteasome inhibition model lacks association with vasa vasorum neovascularisation', EUR HEART J, Jg. 37 , Nr. (Abstract Supplement), S. 21.

APA

Südfeld, S., Wang, F., Hermann, J., Loeffler, D., Lerman, L. O., & Lerman, A. (2016). Early atherosclerosis in a chronic proteasome inhibition model lacks association with vasa vasorum neovascularisation. EUR HEART J, 37 ((Abstract Supplement)), 21.

Vancouver

Südfeld S, Wang F, Hermann J, Loeffler D, Lerman LO, Lerman A. Early atherosclerosis in a chronic proteasome inhibition model lacks association with vasa vasorum neovascularisation. EUR HEART J. 2016;37 ((Abstract Supplement)):21.

Bibtex

@article{15c76453dbac495394b2233d81e71393,
title = "Early atherosclerosis in a chronic proteasome inhibition model lacks association with vasa vasorum neovascularisation",
abstract = "Background: Neovascularisation of the vasa vasorum (VV) is noted in the early stage of atherosclerosis; however, its pathophysiological role remains unclear. Proteasome inhibition has been shown to yield anti-angiogenic effects and to induce and aggravate atherosclerosis in normal (N) and hypercholesterolemic (HC) pigs. Purpose: To test the hypothesis that early atherogenesis develops without concomitant VV neovascularization in the setting of proteasome inhibitor treatment. Methods: Female pigs (n=4 per group) were randomized to either N or HC group without or with additional treatment of the proteasome inhibitor MLN-273 (0.08 mg/kg SQ twice weekly, N+PSI or HC+PSI). The coronary arteries were harvested after twelve weeks and processed for micro-CT imaging and tissue analyses. Results: As presented in the table, compared with N, VV density was increased in HC but not N+PSI or HC+PSI (2.8±0.2 vs. 5.0±0.9, 2.5±0.8, and 2.1±0.1 n/mm2, p<0.05; figure) as was vascular-area-fraction (0.64±0.13 vs. 1.80±0.34, 0.68±0.21, and 0.60±0.07%, p<0.01). Compared with N, the percentage of Ki- 67-positive VV tended to be higher in HC but not in N+PSI or HC+PSI (5.0±1.4 vs. 16.4±4.2, 13.9±9.2, and 1.0±0.4%, p<0.01). HIF-1α expression in the outer media, compared with N, was higher in HC, N+PSI, and HC+PSI (45.0±3.1 vs. 65.9±3.3, 74.8±4.7, and 77.8±3.0%, p<0.01 for HC vs. HC+PSI). VEGF staining per field in the adventitia, compared to N, was increased in HC, but not in N+PSI and HC+PSI (7.08±2.14 vs. 24.76±4.34, 2.52±1.70, and 1.03±0.54%, p<0.01). Conclusions: The current study shows that chronic proteasome inhibition prevents the increase in VV density in HC pigs but does not cause a significant decrease in VV density in N pigs. The underlying pharmaceutical mechanism seems to include the HIF-1α-VEGF-pathway. As chronic proteasome inhibition was shown before to induce and aggravate atherosclerosis in N and HC pigs, the current findings would suggest that the early stage of atherosclerosis did not necessarily require VV neovascularization for its development. Acknowledgement/Funding: National Institutes of Health grants; Mayo Foundation; Mayo Stiftung",
author = "Stefan S{\"u}dfeld and F. Wang and J. Hermann and D. Loeffler and L.O. Lerman and A. Lerman",
note = "moderated poster presentation at the European Society of Cardiology (ESC) Congress 2016 (Rome)",
year = "2016",
language = "Deutsch",
volume = "37 ",
pages = "21",
journal = "EUR HEART J",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "(Abstract Supplement)",

}

RIS

TY - JOUR

T1 - Early atherosclerosis in a chronic proteasome inhibition model lacks association with vasa vasorum neovascularisation

AU - Südfeld, Stefan

AU - Wang, F.

AU - Hermann, J.

AU - Loeffler, D.

AU - Lerman, L.O.

AU - Lerman, A.

N1 - moderated poster presentation at the European Society of Cardiology (ESC) Congress 2016 (Rome)

PY - 2016

Y1 - 2016

N2 - Background: Neovascularisation of the vasa vasorum (VV) is noted in the early stage of atherosclerosis; however, its pathophysiological role remains unclear. Proteasome inhibition has been shown to yield anti-angiogenic effects and to induce and aggravate atherosclerosis in normal (N) and hypercholesterolemic (HC) pigs. Purpose: To test the hypothesis that early atherogenesis develops without concomitant VV neovascularization in the setting of proteasome inhibitor treatment. Methods: Female pigs (n=4 per group) were randomized to either N or HC group without or with additional treatment of the proteasome inhibitor MLN-273 (0.08 mg/kg SQ twice weekly, N+PSI or HC+PSI). The coronary arteries were harvested after twelve weeks and processed for micro-CT imaging and tissue analyses. Results: As presented in the table, compared with N, VV density was increased in HC but not N+PSI or HC+PSI (2.8±0.2 vs. 5.0±0.9, 2.5±0.8, and 2.1±0.1 n/mm2, p<0.05; figure) as was vascular-area-fraction (0.64±0.13 vs. 1.80±0.34, 0.68±0.21, and 0.60±0.07%, p<0.01). Compared with N, the percentage of Ki- 67-positive VV tended to be higher in HC but not in N+PSI or HC+PSI (5.0±1.4 vs. 16.4±4.2, 13.9±9.2, and 1.0±0.4%, p<0.01). HIF-1α expression in the outer media, compared with N, was higher in HC, N+PSI, and HC+PSI (45.0±3.1 vs. 65.9±3.3, 74.8±4.7, and 77.8±3.0%, p<0.01 for HC vs. HC+PSI). VEGF staining per field in the adventitia, compared to N, was increased in HC, but not in N+PSI and HC+PSI (7.08±2.14 vs. 24.76±4.34, 2.52±1.70, and 1.03±0.54%, p<0.01). Conclusions: The current study shows that chronic proteasome inhibition prevents the increase in VV density in HC pigs but does not cause a significant decrease in VV density in N pigs. The underlying pharmaceutical mechanism seems to include the HIF-1α-VEGF-pathway. As chronic proteasome inhibition was shown before to induce and aggravate atherosclerosis in N and HC pigs, the current findings would suggest that the early stage of atherosclerosis did not necessarily require VV neovascularization for its development. Acknowledgement/Funding: National Institutes of Health grants; Mayo Foundation; Mayo Stiftung

AB - Background: Neovascularisation of the vasa vasorum (VV) is noted in the early stage of atherosclerosis; however, its pathophysiological role remains unclear. Proteasome inhibition has been shown to yield anti-angiogenic effects and to induce and aggravate atherosclerosis in normal (N) and hypercholesterolemic (HC) pigs. Purpose: To test the hypothesis that early atherogenesis develops without concomitant VV neovascularization in the setting of proteasome inhibitor treatment. Methods: Female pigs (n=4 per group) were randomized to either N or HC group without or with additional treatment of the proteasome inhibitor MLN-273 (0.08 mg/kg SQ twice weekly, N+PSI or HC+PSI). The coronary arteries were harvested after twelve weeks and processed for micro-CT imaging and tissue analyses. Results: As presented in the table, compared with N, VV density was increased in HC but not N+PSI or HC+PSI (2.8±0.2 vs. 5.0±0.9, 2.5±0.8, and 2.1±0.1 n/mm2, p<0.05; figure) as was vascular-area-fraction (0.64±0.13 vs. 1.80±0.34, 0.68±0.21, and 0.60±0.07%, p<0.01). Compared with N, the percentage of Ki- 67-positive VV tended to be higher in HC but not in N+PSI or HC+PSI (5.0±1.4 vs. 16.4±4.2, 13.9±9.2, and 1.0±0.4%, p<0.01). HIF-1α expression in the outer media, compared with N, was higher in HC, N+PSI, and HC+PSI (45.0±3.1 vs. 65.9±3.3, 74.8±4.7, and 77.8±3.0%, p<0.01 for HC vs. HC+PSI). VEGF staining per field in the adventitia, compared to N, was increased in HC, but not in N+PSI and HC+PSI (7.08±2.14 vs. 24.76±4.34, 2.52±1.70, and 1.03±0.54%, p<0.01). Conclusions: The current study shows that chronic proteasome inhibition prevents the increase in VV density in HC pigs but does not cause a significant decrease in VV density in N pigs. The underlying pharmaceutical mechanism seems to include the HIF-1α-VEGF-pathway. As chronic proteasome inhibition was shown before to induce and aggravate atherosclerosis in N and HC pigs, the current findings would suggest that the early stage of atherosclerosis did not necessarily require VV neovascularization for its development. Acknowledgement/Funding: National Institutes of Health grants; Mayo Foundation; Mayo Stiftung

M3 - Konferenz-Abstract in Fachzeitschrift

VL - 37

SP - 21

JO - EUR HEART J

JF - EUR HEART J

SN - 0195-668X

IS - (Abstract Supplement)

ER -